Latest Property Portfolio News

Adisyn Ltd has successfully completed a key R&D program on low-temperature graphene deposition, earning full approval and final payment of a $520,000 grant from the Israel Innovation Authority. This milestone validates its cutting-edge semiconductor technology aimed at revolutionizing AI and high-performance computing.

Mesoblast reports positive FDA progress on accelerated approval for Revascor in ischemic heart failure and plans a pivotal trial to extend Ryoncil’s label to adults with graft versus host disease, while its US commercial launch outpaces expectations.

Cyclopharm Limited has secured the maximum five-year U.S. patent extension for its flagship Technegas® Kit, extending market exclusivity to 2031 and reinforcing its strategic foothold in pulmonary imaging.

CAQ Holdings Limited has successfully restructured its debt repayment schedule and secured a new RMB 6 million loan facility, positioning itself to support operational growth amid efforts to increase occupancy rates.

Recce Pharmaceuticals has secured a significant patent acceptance in China for its RECCE® anti-infectives, broadening its intellectual property footprint in the world’s second-largest pharmaceutical market.

Argenica Therapeutics has expanded its intellectual property with a new US patent targeting surgically induced strokes, enhancing the commercial potential of its lead drug candidate ARG-007.

Australian Agricultural Company Limited (AACo) reported a 14% rise in operating profit to $58.4 million for FY25, driven by increased sales volumes and disciplined cost control despite challenging market conditions. The company also marked a significant reduction in statutory loss, signaling improved financial resilience.

Anatara Lifesciences has expanded its intellectual property footprint with a 20-year patent granted in Hong Kong for its GaRP gastrointestinal health product, following similar approvals in Europe and Australia. This milestone strengthens its commercial position in the lucrative global market for digestive health solutions.

Mesoblast has been granted a seven-year orphan-drug exclusivity by the FDA for its cell therapy Ryoncil, reinforcing its market position in treating steroid-refractory acute graft versus host disease in children.

Abacus Storage King reports a 5.5% uplift in its property portfolio valuation as of March 2025, driven by improved operations and recent developments. This boost is expected to increase net tangible assets by around $0.13 per security.

Growthpoint Properties Australia has raised its FY25 funds from operations guidance and expanded its logistics portfolio with a $40 million industrial asset acquisition in Queensland, signaling strong operational momentum.

ANZ Group Holdings Limited posted a 7% increase in statutory profit to AUD 3.642 billion for the half year ended 31 March 2025, with stable cash profit and an 83 cent interim dividend. The full integration of Suncorp Bank underpinned lending and deposit growth, while credit impairments eased.